Parameter
|
4w
|
6w
|
---|
Normal group
|
NAFLD group
|
Normal group
|
Low-dose group
|
Middle-dose group
|
High-dose group
|
Positive control group
|
---|
AST (U/L)
|
75.17 ± 4.31
|
96.85 ± 7.63★★
|
76.29 ± 5.16
|
97.36 ± 6.82**
|
93.75 ± 4.55*
|
88.34 ± 6.27*#
|
101.67 ± 8.36
|
ALT(U/L)
|
28.16 ± 1.21
|
51.28 ± 3.26★★
|
29.25 ± 1.72
|
53.28 ± 4.41**
|
49.78 ± 2.19**
|
44.29 ± 2.22**#
|
56.35 ± 4.16
|
TG(mmol/L)
|
0.59 ± 0.09
|
1.65 ± 0.08★★
|
0.61 ± 0.04
|
1.81 ± 0.11**
|
1.46 ± 0.09**#
|
0.92 ± 0.03**##
|
2.12 ± 0.12
|
TC(mmol/L)
|
1.66 ± 0.12
|
3.14 ± 0.13★★
|
1.70 ± 0.09
|
3.82 ± 0.15**
|
3.65 ± 0.17**#
|
2.65 ± 0.12**##
|
4.54 ± 0.24
|
LDL-C (mmol/L)
|
0.54 ± 0.03
|
1.25 ± 0.08★★
|
0.56 ± 0.04
|
1.37 ± 0.08**
|
1.24 ± 0.05**
|
1.09 ± 0.06**#
|
1.35 ± 0.09
|
HDL-C (mmol/L)
|
0.96 ± 0.04
|
0.64 ± 0.04★★
|
0.98 ± 0.05
|
0.64 ± 0.03**
|
0.69 ± 0.05**
|
0.77 ± 0.04*#
|
0.55 ± 0.03
|
GLU (mmol/L)
|
4.68 ± 0.15
|
5.07 ± 0.21
|
4.56 ± 0.18
|
4.99 ± 0.87
|
5.07 ± 0.04
|
5.13 ± 18.88
|
5.41 ± 0.19
|
TBA(μmol/L)
|
6.75 ± 0.05
|
10.23 ± 0.06★★
|
6.54 ± 0.06
|
11.53 ± 1.27**
|
11.04 ± 0.98**
|
10.24 ± 0.05**#
|
12.27 ± 1.25
|
Leptin (μg/L)
|
0.18 ± 0.01
|
0.32 ± 0.01★
|
0.19 ± 0.02
|
0.46 ± 0.03**
|
0.34 ± 0.02*#
|
0.28 ± 0.01#
|
0.46 ± 0.03
|
SOD (U/mL)
|
374.36 ± 17.86
|
300.4 ± 20.1★★
|
370.35 ± 19.46
|
293.4 ± 24.1**
|
321.79 ± 23.16*
|
348.32 ± 19.76#
|
297.84 ± 23.17
|
MDA (nmol/mL)
|
3.26 ± 0.21
|
4.27 ± 0.16★★
|
3.25 ± 0.75
|
4.98 ± 1.32*
|
4.77 ± 0.87*
|
3.84 ± 0.99##
|
5.04 ± 1.27
|
GSH-Px (U/mL)
|
256.21 ± 19.25
|
210.45 ± 14.2★
|
255.98 ± 20.54
|
206.88 ± 15.3**
|
211.57 ± 17.45**#
|
238.78 ± 14.25#
|
194.21 ± 17.35
|
-
★
P < 0.05, ★★
P < 0.01, compared to normal control group (4w). *P < 0.05, **P < 0.01, compared to normal group (6w); #
P < 0.05, ##
P < 0.01, compared to positive control group (6w). Normal Group: the group was given normal diet (n = 20) for 4 weeks; NAFLD Group: the group was given high-fat diet (n = 20) for 4 weeks;Negative Control Group: After the normal diet of 4 weeks, the group was given normal diet (n = 20) for 6 weeks; Low-dose group: After the HFD of 4 weeks, the group was administered TFSC orally once a day at a low dose of 100 mg/kg (n = 20) for 6 weeks; Middle-dose group: After the HFD of 4 weeks, the group was administered TFSC orally once a day at a medium dose of 200 mg/kg (n = 20) for 6 weeks; High-dose group: After the HFD of 4 weeks, the group was administered TFSC orally once a day at a high dose of 400 mg/kg (n = 20) for 6 weeks; Positive control group: After the HFD of 4 weeks, the group was given high-fat diet (n = 20) for 6 weeks